Enanta Pharmaceuticals (NASDAQ:ENTA) Given Buy Rating at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Enanta Pharmaceuticals (NASDAQ:ENTA) in a research note published on Friday,Benzinga reports. HC Wainwright currently has a $20.00 target price on the biotechnology company’s stock.

A number of other brokerages also recently commented on ENTA. JPMorgan Chase & Co. assumed coverage on Enanta Pharmaceuticals in a research note on Friday, November 14th. They issued an “overweight” rating and a $17.00 target price for the company. Weiss Ratings restated a “sell (d-)” rating on shares of Enanta Pharmaceuticals in a research report on Wednesday, October 8th. Evercore ISI dropped their target price on Enanta Pharmaceuticals from $20.00 to $12.00 and set an “outperform” rating on the stock in a research report on Monday, September 15th. Westpark Capital raised their target price on Enanta Pharmaceuticals from $24.00 to $28.00 and gave the company a “buy” rating in a research note on Tuesday, September 30th. Finally, Jefferies Financial Group raised shares of Enanta Pharmaceuticals from a “hold” rating to a “buy” rating and boosted their price target for the company from $14.00 to $20.00 in a report on Wednesday, October 1st. Six research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $20.33.

Enanta Pharmaceuticals Price Performance

ENTA stock opened at $13.11 on Friday. The firm has a market cap of $378.35 million, a price-to-earnings ratio of -3.42 and a beta of 0.95. Enanta Pharmaceuticals has a 1-year low of $4.09 and a 1-year high of $17.15. The firm has a fifty day moving average price of $13.81 and a two-hundred day moving average price of $10.46.

Enanta Pharmaceuticals (NASDAQ:ENTA) last posted its quarterly earnings results on Monday, November 17th. The biotechnology company reported ($0.87) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.13) by $0.26. Enanta Pharmaceuticals had a negative net margin of 125.36% and a negative return on equity of 93.76%. The company had revenue of $15.13 million for the quarter, compared to the consensus estimate of $15.60 million. As a group, analysts expect that Enanta Pharmaceuticals will post -4.65 EPS for the current fiscal year.

Insider Activity at Enanta Pharmaceuticals

In other news, insider Yat Sun Or sold 2,390 shares of Enanta Pharmaceuticals stock in a transaction on Friday, December 5th. The stock was sold at an average price of $14.23, for a total transaction of $34,009.70. Following the transaction, the insider directly owned 371,392 shares in the company, valued at approximately $5,284,908.16. This trade represents a 0.64% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Jay R. Luly sold 4,743 shares of the business’s stock in a transaction on Friday, December 5th. The stock was sold at an average price of $14.23, for a total value of $67,492.89. Following the completion of the sale, the chief executive officer directly owned 858,026 shares in the company, valued at $12,209,709.98. This represents a 0.55% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 11,961 shares of company stock worth $170,149 over the last quarter. 13.89% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of ENTA. Public Employees Retirement System of Ohio raised its position in Enanta Pharmaceuticals by 8.3% in the third quarter. Public Employees Retirement System of Ohio now owns 14,412 shares of the biotechnology company’s stock worth $173,000 after acquiring an additional 1,100 shares in the last quarter. Ameriprise Financial Inc. raised its holdings in shares of Enanta Pharmaceuticals by 8.3% in the 3rd quarter. Ameriprise Financial Inc. now owns 18,007 shares of the biotechnology company’s stock worth $216,000 after purchasing an additional 1,383 shares in the last quarter. AlphaQuest LLC raised its holdings in shares of Enanta Pharmaceuticals by 18.1% in the 3rd quarter. AlphaQuest LLC now owns 10,198 shares of the biotechnology company’s stock worth $122,000 after purchasing an additional 1,562 shares in the last quarter. Sio Capital Management LLC lifted its stake in Enanta Pharmaceuticals by 1.0% during the second quarter. Sio Capital Management LLC now owns 178,774 shares of the biotechnology company’s stock valued at $1,352,000 after purchasing an additional 1,770 shares during the last quarter. Finally, Russell Investments Group Ltd. boosted its holdings in Enanta Pharmaceuticals by 13.4% during the third quarter. Russell Investments Group Ltd. now owns 16,443 shares of the biotechnology company’s stock worth $197,000 after buying an additional 1,940 shares in the last quarter. 94.99% of the stock is owned by institutional investors and hedge funds.

Enanta Pharmaceuticals Company Profile

Enanta Pharmaceuticals, Inc is a biotechnology company headquartered in Watertown, Massachusetts, specializing in the discovery and development of novel, small-molecule drugs targeting viral diseases. Leveraging a proprietary chemistry platform, Enanta has built extensive expertise in designing potent inhibitors of viral proteases and polymerases. The company initially gained recognition through partnerships focused on hepatitis C virus (HCV), where its protease inhibitors formed a key component of ABBVIE’s direct‐acting antiviral regimens.

Building on its HCV experience, Enanta has expanded its pipeline to address respiratory syncytial virus (RSV) and other viral infections.